“As we think about the phasing, we would expect each quarter to get a little better.”

In context

“g down mid-singles, getting to low-single digits up for the year. As you look at the operating businesses there, can you just call out, is there anything that stands out as one-off, or notable in terms of the ramp? I mean, just when in the year will you return to growth? Is 2Q reasonable or is it more back-half weighted? Rainer Blair: So, Jack, good morning, and thanks for the question. For 2025 in Life Sciences, it's the one segment where we see a little bit of noise right now with the external environment. But given that, we're trying to take a reasonably prudent approach to the guide for 2025 and we're assuming Life Science tools up for - up low-single digits and Pall and Genomics will be down. So we'll possibly do better, but where we sit today, this is probably a good starting point. As we think about the phasing, we would expect each quarter to get a little better. Matt McGrew: Okay. Jack, maybe - just Q1, like you said, it's kind of down mid-single digits. I think we probably are kind of flattish as we head into Q2, and then kind of ramp up from there. And really Q1, the big kind of comp issue is a lot of it really is Pall, in particular, some of the things in the industrial business, both year-over-year with some big projects that we saw there and then also sequentially kind of the step-down. If you will, from Q4 in Life Sciences, they were a double-digit grower here in Q4. I think they're going to be negative here in Q1. And given the size of that business, it's almost $2 billion. It does kind of move the needle. But the core tools we think is still in pretty good shape and kind of at the high end of low-single digits. Jack Meehan: Great. Okay. A”